米氮平联合丁螺环酮治疗躯体化障碍对照研究

目的：探讨米氮平联合丁螺环酮治疗躯体化障碍的临床疗效和安全性。方法将60例躯体化障碍患者随机为两组，每组30例，均口服米氮平治疗，观察组联合丁螺环酮治疗，观察6周。于治疗前后采用汉密顿焦虑量表、汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组汉密顿焦虑量表、汉密顿抑郁量表评分均较治疗前有显著下降（P＜0．01），同期观察组较对照组下降更显著（ P＜0．05或0．01）；治疗6周末观察组抗焦虑、抗抑郁有效率均显著高于对照组（P＜0．05）。两组不良反应均轻微，副反应量表评分及不良反应发生率差异均无显著性（P＞0．05）。结论米氮平联合丁螺环酮治疗躯体化障碍患者具有增效作用，疗效显著，起效快，安全性高，依从性好，显著优于单用米氮平治疗。

A control study of mirtazapine combined with buspirone in the treatment of somatization disorder

Objective To explore the efficacy and safety of mirtazapine combined with buspirone in the treatment of somatization disorder （SD） .Methods Sixty SD patients were randomly divided into two groups of 30 ones each ,both groups took orally mirtazapine ,and observation group was plus buspirone for 6 weeks .Efficacies were assessed with the Hamilton Anxiety Scale （HAMA） and Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before and af-ter treatment .Results The HAMA and HAMD scores of both groups lowered more significantly after treatment compared with pre-treatment （P〈0 .01） ,so did those in observation than in control group in the corresponding period （P〈0 .05 or 0 .01）;antianxiety and antidepressant effective rate were significantly higher in research than control group at the end of the 6th week （P〈 0 .05） .Adverse reactions of both groups were mild ,there were no significant group differences in the TESS scores and incidences of adverse reactions （P〉 0 .05） .Conclusion Mirtazapine combined with buspirone has synergism and an evident effect ,takes effect more rapidly and has higher safety and better compliance compared with single mirtaza-pine in the treatment of somatization disorder .